ATE430557T1 - Liposomen - Google Patents

Liposomen

Info

Publication number
ATE430557T1
ATE430557T1 AT02769160T AT02769160T ATE430557T1 AT E430557 T1 ATE430557 T1 AT E430557T1 AT 02769160 T AT02769160 T AT 02769160T AT 02769160 T AT02769160 T AT 02769160T AT E430557 T1 ATE430557 T1 AT E430557T1
Authority
AT
Austria
Prior art keywords
liposomes
internalised
internalisation
entrapped
compounds
Prior art date
Application number
AT02769160T
Other languages
German (de)
English (en)
Inventor
Sigrid Fossheim
Liv Odegardstuen
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Application granted granted Critical
Publication of ATE430557T1 publication Critical patent/ATE430557T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT02769160T 2001-05-10 2002-05-10 Liposomen ATE430557T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0111279.6A GB0111279D0 (en) 2001-05-10 2001-05-10 Radiolabelled liposomes
PCT/GB2002/002100 WO2002089771A1 (en) 2001-05-10 2002-05-10 Liposomes

Publications (1)

Publication Number Publication Date
ATE430557T1 true ATE430557T1 (de) 2009-05-15

Family

ID=9914262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02769160T ATE430557T1 (de) 2001-05-10 2002-05-10 Liposomen

Country Status (8)

Country Link
US (1) US20040170560A1 (https=)
EP (1) EP1385480B1 (https=)
JP (1) JP4629308B2 (https=)
AT (1) ATE430557T1 (https=)
DE (1) DE60232237D1 (https=)
ES (1) ES2323493T3 (https=)
GB (1) GB0111279D0 (https=)
WO (1) WO2002089771A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101133084B1 (ko) * 2002-12-31 2012-04-04 자이더스 비에스브이 파마 프라이빗 리미티드 장기간 순환성 비-페길레이티드 리포좀
DE602004027655D1 (de) * 2003-11-03 2010-07-22 Yissum Res Dev Co Verfahren zur auswahl von kationischen oder anionischen liposomen zur behandlung einer schleimhautmembran und diese enthaltendes set
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
EP3415151A1 (en) * 2008-05-23 2018-12-19 The University of British Columbia Modified drugs for use in liposomal nanoparticles
CA2746527A1 (en) * 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
AU2010270722B2 (en) * 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN105168135A (zh) * 2010-03-12 2015-12-23 博格有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
BR112013027413A2 (pt) * 2011-04-26 2019-09-24 Cedars Sinai Medical Center vancomicina lipossomal para o tratamento de infecções de sarm.
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
US20140023696A1 (en) * 2012-07-20 2014-01-23 Frederick Timothy Guilford Treatment for idiopathic pulmonary fibrosis
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
WO2015023797A1 (en) * 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
CA2963931A1 (en) 2014-10-06 2016-04-14 Exicure, Inc. Anti-tnf compounds
WO2016085986A1 (en) 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
CN105434368A (zh) * 2014-11-27 2016-03-30 广州白云山明兴制药有限公司 一种注射用还原型谷胱甘肽及其预冻方法
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
JP2020526558A (ja) 2017-07-13 2020-08-31 ノースウェスタン ユニバーシティ オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6137735A (ja) * 1984-07-31 1986-02-22 Terumo Corp ヘモグロビン含有リポソ−ムおよびその製造方法
DE69018460T2 (de) * 1989-04-18 1995-11-09 Vestar Inc Markierung mit liposomen von ischämischen geweben.
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5143713A (en) * 1990-05-30 1992-09-01 Board Of Regents, The University Of Texas System 99m Tc labeled liposomes
AU3244393A (en) * 1992-12-02 1994-06-22 Vestar, Inc. Antibiotic formulation and process
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
JPH11171772A (ja) * 1997-12-11 1999-06-29 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤
MXPA01010977A (es) * 1999-04-29 2002-07-22 Alza Corp Composiciones de liposoma para la retencion mejorada del medicamento.
CA2340757A1 (en) * 1999-07-07 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Delivery of liposomal-encapsulated antioxidants and applications thereof

Also Published As

Publication number Publication date
JP4629308B2 (ja) 2011-02-09
GB0111279D0 (en) 2001-06-27
ES2323493T3 (es) 2009-07-17
US20040170560A1 (en) 2004-09-02
EP1385480A1 (en) 2004-02-04
WO2002089771A1 (en) 2002-11-14
EP1385480B1 (en) 2009-05-06
JP2004529163A (ja) 2004-09-24
DE60232237D1 (de) 2009-06-18

Similar Documents

Publication Publication Date Title
DE60232237D1 (de) Liposomen
AR024839A1 (es) Compuesto bi o triciclico sustituido, su uso en la fabricacion de un medicamento y composicion farmaceutica que lo comprende.
GT200400242A (es) Uso extendido de combinacion que comprende estrogenos y progestina.
DE69907977D1 (de) Pyrrolobenzodiazepine
ES2130575T3 (es) Composiciones inmunogenicas mejoradas contra la gastrina 17 humana.
DE50109960D1 (de) Therapeutische und diagnostische ligandensysteme mit transportmolekülbindenden eigenschaften und diese enthaltende arzneimittel
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
DE59707812D1 (de) Opioidantagonisthaltige galenische formulierung
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
CY1105144T1 (el) Χρηση μιας ουσιας που συνδεεται στον πepιφepειακο υποδοχεα των βενζοδιαζεπινων στη θepαπεια του δepματικου στρες
SE8700499D0 (sv) Novel pharmacologically active compounds
DE60212734D1 (de) Pharmazeutische Zubereitung enthaltend Doxazosin
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
ATE312080T1 (de) 2-chinolonen enthaltende arzneimittel
CL2004000551A1 (es) Compuestos derivados de triazol sustituidos con biarilo, sus sales, bloqueadores del canal de sodio; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento o prevencion del dolor.
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
ID26055A (id) Senyawa-senyawa hidroksidifenil eter
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
DE60112756D1 (de) Racecadotril enthaltende trockene pulverformulierung
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
ES2161292T3 (es) Composicion de higiene oral.
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
DE60025503D1 (de) Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
TW200509863A (en) Irradiation device for medical use
CY1106319T1 (el) Τοπικη θepαπεια στη μασταλγια

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties